Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing therapeutic resistance in cancer. The company's research and development team is developing clinical therapies to counter resistance mechanisms in cancer, specifically in hormone-dependent cancers, precision oncology, and key tumor dependencies. ORIC Pharmaceuticals' clinical-stage product candidates include Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. The company licensed the development and commercialization rights for Rinzimetostat from Mirati Therapeutics, Inc. under a license agreement. An Investigational New Drug application (IND) for Rinzimetostat was filed and cleared with the Food and Drug Administration (FDA) in the fourth quarter of 2021. ORIC Pharmaceuticals completed a Phase 1b trial of Rinzimetostat as a single-agent in patients with advanced prostate cancer, reporting initial Phase 1b data in January 2024. In July 2024, the company announced that in the first half of 2024, it initiated dosing of Rinzimetostat in combination with apalutamide and in combination with darolutamide, as part of the ongoing Phase 1b trial in patients with metastatic castration resistant prostate cancer (mCRPC).